Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Tianda Pharmaceuticals Ltd. (0455) Stock Price & Analysis

0 Followers

0455 Stock Chart & Stats

HK$0.07HK$0.00(1.37%)
At close: 4:00 PM GMT+8
HK$0.075HK$0.1HK$0.125Aug 17Sep 1Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 0.07 - HKD 0.09
52-Week Range
HKD 0.07 - HKD 0.14
Previous Close
HKD 0.07
Volume
N/A
Average Volume (3M)
121.00K
Market Cap
HKD 156.95M
Enterprise Value
HKD 284.88M
Total Cash (Recent Filing)
HKD 64.81M
Total Debt (Recent Filing)
HKD 132.66M
Price to Earnings (P/E)
―
Beta
0.74
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Jun 13, 2024
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Manageable Leverage

Moderate leverage suggests the company is not heavily burdened by debt and retains some financial flexibility. This can support continued operations and selective investment, although the benefit depends on improving profitability and preventing further erosion of equity.

Positive 2025 Operating Cash Flow

The return to positive operating and free cash flow in 2025 indicates some improvement in cash conversion and near-term funding capacity. If maintained, this could reduce reliance on external financing and provide resources for ongoing pharmaceutical operations.

Resilient Gross Margin

A gross margin of about 41% remains relatively healthy for the industry, showing that the company retains meaningful product-level economics despite recent compression. Preserving this margin could support recovery if revenue stabilizes and operating costs become better controlled.

Bears Say

Persistent Losses And Margin Deterioration

Persistent losses and a sharply weaker net margin indicate that the current business model is not translating revenue into sustainable earnings. Continued negative EBIT and net income can restrict reinvestment, weaken equity, and make a durable financial recovery more difficult.

Declining Revenue Trend

A multi-period revenue decline limits operating leverage and makes it harder to absorb fixed costs across the business. Unless sales regain a durable growth trajectory, the company has less opportunity to improve profitability, fund development, or strengthen its competitive position.

Volatile Cash Generation

Although cash flow turned positive in 2025, the preceding volatility and repeated negative free cash flow show that cash generation has not yet become dependable. Unstable internal funding can constrain investment and increase execution risk during periods of weak profitability.

Tianda Pharmaceuticals Ltd. News

0455 FAQ

What was Tianda Pharmaceuticals Ltd.’s price range in the past 12 months?
Tianda Pharmaceuticals Ltd. lowest stock price was HK$0.07 and its highest was HK$0.14 in the past 12 months.
What is Tianda Pharmaceuticals Ltd.’s market cap?
Tianda Pharmaceuticals Ltd.’s market cap is HK$156.95M.
When is Tianda Pharmaceuticals Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tianda Pharmaceuticals Ltd.’s earnings last quarter?
Tianda Pharmaceuticals Ltd. released its earnings results on Aug 10, 2026. The company reported -HK$0.015 earnings per share for the quarter.
Is Tianda Pharmaceuticals Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Tianda Pharmaceuticals Ltd. pay dividends?
Tianda Pharmaceuticals Ltd. pays a dividend of HK$0.003 which represents an annual dividend yield of ―. See more information on Tianda Pharmaceuticals Ltd. dividends here
What is Tianda Pharmaceuticals Ltd.’s EPS estimate?
Tianda Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianda Pharmaceuticals Ltd. have?
Tianda Pharmaceuticals Ltd. has 2,150,041,700 shares outstanding.
What happened to Tianda Pharmaceuticals Ltd.’s price movement after its last earnings report?
Tianda Pharmaceuticals Ltd. reported an EPS of -HK$0.015 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tianda Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:0455
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology